| 中文名称: | 唑来磷酸一水化合物 促销 文献数量：1 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | Zoledronic acid monohydrate | ||||
| 别名: | 唑来磷酸一水化合物 P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate | ||||
| CAS No: | 165800-06-6 | 分子式: | C5H10N2O7P2.H2O | 分子量: | 290.1 |
| CAS No: | 165800-06-6 | ||||
| 分子式: | C5H10N2O7P2.H2O | ||||
| 分子量: | 290.1 | ||||
| MDL: | MFCD08448695 | ||||
基本信息
|
产品编号：Z10002 |
|||||
|
产品名称：Zoledronic acid monohydrate |
|||||
|
CAS: |
165800-06-6 |
储存条件 |
粉末 |
2-8℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
290.10 |
-20℃ |
一个月 |
||
|
化学名： |
(1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid hydrate |
||||
|
Solubility (25°C) |
体外 |
DMSO |
0.01mg/mL (0.03mM) |
||
|
Ethanol |
Insoluble |
||||
|
Water |
Insoluble |
||||
|
体内 |
现配现用 |
|
|||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
3.4471mL |
17.2354mL |
34.4709mL |
|
5mM |
0.6894mL |
3.4471mL |
6.8942mL |
|
10mM |
0.3447mL |
1.7235mL |
3.4471mL |
生物活性
|
产品描述 |
一种高活性的双膦酸盐和PKC激活剂。 |
|
|
靶点/IC50 |
Ras |
Rho |
|
体外研究 |
Zoledronic Acid monohydrate (0.1-1 µM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells. Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells. Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells. Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Zoledronic Acid monohydrate (10-100µM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells. Zoledronic Acid monohydrate (10-100µM; 1-7 days) induces apoptosis in MC3T3-E1 cells. Zoledronic Acid monohydrate (10-100µM; 4 days) inhibits cell viability due to the induction of apoptosis. Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1µM. Cell Viability Assay |
|
|
Cell Line: |
MC3T3-E1 cells |
|
|
Concentration: |
0.02µM , 0.1µM, 1µM, 10µM, 100µM |
|
|
Incubation Time: |
1day, 3days, 5days, 7days |
|
|
Result: |
Reduced cells viability at 10µM and 100µM. |
|
|
Apoptosis Analysis |
||
|
Cell Line: |
MC3T3-E1 cells |
|
|
Concentration: |
0.02µM , 0.1µM, 1µM, 10µM, 100µM |
|
|
Incubation Time: |
1days, 4days, 7days |
|
|
Result: |
Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dosedependent and time-dependent (high concentrations). |
|
|
Western Blot Analysis |
||
|
Cell Line: |
MC3T3-E1 cells |
|
|
Concentration: |
0.02µM , 0.1µM, 1µM, 10µM, 100µM |
|
|
Incubation Time: |
4days |
|
|
Result: |
Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100µM. |
|
|
体内研究 |
Zoledronic Acid monohydrate (0.05mg/kg; i.p.; weekly; for 3weeks) increases bone mineral density and content. Zoledronic Acid monohydrate (0.5-1mg/kg; i.p.; weekly; for 3weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties. |
|
|
Animal Model: |
Five-week-old C57BL6 mice |
|
|
Dosage: |
0.05mg/kg, 0.5mg/kg, 1mg/kg |
|
|
Administration: |
Intraperitoneal injection, weekly, for 3weeks |
|
|
Result: |
Intraperitoneal injection, weekly, for 3weeks. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
